MONARCH 3: Final overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor as first-line therapy for HR+, HER2-advanced breast cancer

被引：1
|
作者：
Goetz, Matthew
Toi, Masakazu
Huober, Jens
Sohn, Joo Hyuk
Tredan, Olivier
Park, Inhae
Campone, Mario
Chen, Shin-Cheh
Manso, Luis Manual
Paluch-Shimon, Shani
Freedman, Orit C.
Andre, Valerie
Saha, Abhijoy
van Hal, Gertjan
Shahir, Ashwin
Iwata, Hiroji
Johnston, Stephen R. D.
O'Shaughnessy, Joyce
Pivot, Xavier
Tolaney, Sara
Hurvitz, Sara
Llombart, Antonio
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-GS01-12
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
GS01-12
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Health-related quality of life in MONARCH 3: Abemaciclib plus an aromatase inhibitor as initial therapy in women with HR-positive (HR+), HER2-negative (HER2-) advanced breast cancer
    Goetz, M. P.
    Johnston, S.
    Martin, M.
    Tokunaga, E.
    Park, I. H.
    Huober, J.
    Toi, M.
    Price, G. L.
    Boye, M.
    Li, L.
    Forrester, T.
    Gainford, C.
    Gable, J.
    Carter, G. C.
    Sood, A.
    Dileo, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 288 - 289
  • [32] MONARCH 3: Updated time to chemotherapy and disease progression following abemaciclib plus aromatase inhibitor (AI) in HR1, HER2-advanced breast cancer (ABC)
    Martin, M.
    Johnston, S.
    Huober, J.
    Di Leo, A.
    Sohn, J.
    Andre, V. A.
    Martin, H. R.
    Hardebeck, M. C.
    Goetz, M. P.
    ANNALS OF ONCOLOGY, 2019, 30 : 113 - +
  • [33] Cost Effectiveness of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Pre-/Perimenopausal, HR+ and HER2-Advanced Breast Cancer: A Canadian Healthcare Perspective
    Stellato, Daniel
    Thabane, Marroon E.
    Chandiwana, David
    Park, Jinhee
    Delea, Thomas E.
    PHARMACOECONOMICS, 2021, 39 (07) : 853 - 867
  • [34] Management of abemaciclib-associated adverse events in patients with HR+/HER2-advanced breast cancer: analysis of the MONARCH trials
    Rugo, H. S.
    Huober, J.
    Llombart-Cussac, A.
    Toi, M.
    Tolaney, S.
    Andre, V.
    Barriga, S.
    Forrester, T.
    Sledge, Jr G. W.
    Goetz, M. P.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 289 - 289
  • [35] Quality of life with ribociclib versus abemaciclib as first-line treatment of HR+/HER2-advanced breast cancer: a matching-adjusted indirect comparison
    Rugo, Hope S. S.
    Harmer, Victoria
    O'Shaughnessy, Joyce
    Jhaveri, Komal
    Tolaney, Sara M. M.
    Cardoso, Fatima
    Bardia, Aditya
    Maheshwari, Vikalp Kumar
    Tripathi, Sandeep
    Haftchenary, Sina
    Pathak, Purnima
    Fasching, Peter A. A.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [36] MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2-Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
    Sledge, George W., Jr.
    Toi, Masakazu
    Neven, Patrick
    Sohn, Joohyuk
    Inoue, Kenichi
    Pivot, Xavier
    Burdaeva, Olga
    Okera, Meena
    Masuda, Norikazu
    Kaufman, Peter A.
    Koh, Han
    Grischke, Eva-Maria
    Frenzel, Martin
    Lin, Yong
    Barriga, Susana
    Smith, Ian C.
    Bourayou, Nawel
    Llombart-Cussac, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (25) : 2875 - +
  • [37] The prognostic impact of BMI in patients with HR+/HER2-advanced breast cancer on first-line endocrine therapy with or without a CDK 4/6 inhibitor
    Lammers, S.
    Thurisch, H.
    Vriens, I. J. H.
    Meegdes, M.
    Engelen, S. M. E.
    Erdkamp, F. L. G.
    Dercksen, M.
    Vriens, B.
    Aaldering, K.
    Pepels, M.
    Winkel, L. V. D.
    Peters, N.
    Tol, J.
    Heijns, J. B.
    van de Wouw, A.
    Teeuwen, N.
    Geurts, S.
    Tjan-Heijnen, V.
    ANNALS OF ONCOLOGY, 2023, 34 : S345 - S345
  • [38] Palbociclib Plus Fulvestrant Maintains Long-Term Overall Survival Benefit in HR+/HER2-Advanced Breast Cancer
    不详
    ONCOLOGIST, 2021, 26 : S5 - S6
  • [39] Everolimus plus exemestane as first-line therapy in HR+, HER2− advanced breast cancer in BOLERO-2
    J. Thaddeus Beck
    Gabriel N. Hortobagyi
    Mario Campone
    Fabienne Lebrun
    Ines Deleu
    Hope S. Rugo
    Barbara Pistilli
    Norikazu Masuda
    Lowell Hart
    Bohuslav Melichar
    Shaker Dakhil
    Matthias Geberth
    Martina Nunzi
    Daniel Y. C. Heng
    Thomas Brechenmacher
    Mona El-Hashimy
    Shyanne Douma
    Francois Ringeisen
    Martine Piccart
    Breast Cancer Research and Treatment, 2014, 143 : 459 - 467
  • [40] Everolimus plus exemestane as first-line therapy in HR+, HER2- advanced breast cancer in BOLERO-2
    Beck, J. Thaddeus
    Hortobagyi, Gabriel N.
    Campone, Mario
    Lebrun, Fabienne
    Deleu, Ines
    Rugo, Hope S.
    Pistilli, Barbara
    Masuda, Norikazu
    Hart, Lowell
    Melichar, Bohuslav
    Dakhil, Shaker
    Geberth, Matthias
    Nunzi, Martina
    Heng, Daniel Y. C.
    Brechenmacher, Thomas
    El-Hashimy, Mona
    Douma, Shyanne
    Ringeisen, Francois
    Piccart, Martine
    BREAST CANCER RESEARCH AND TREATMENT, 2014, 143 (03) : 459 - 467
12345